The Effects of Cancer’s Metastatic Status and Chemotherapy on Totally Implantable Venous Access Port Patency and Port-Related Venous Thromboembolic Events
S. Yazman, B. Depboylu, Bengü Depboylu, Emine Depboylu, B. Harmandar
{"title":"The Effects of Cancer’s Metastatic Status and Chemotherapy on Totally Implantable Venous Access Port Patency and Port-Related Venous Thromboembolic Events","authors":"S. Yazman, B. Depboylu, Bengü Depboylu, Emine Depboylu, B. Harmandar","doi":"10.52831/kjhs.1272466","DOIUrl":null,"url":null,"abstract":"Objectives: Totally implantable venous access port(TIVAP) is of great importance as a vascular access route in the treatment of cancer patients. In this study, we researched the effects of cancer types, metastases, chemotherapeutic drugs, and intervention sites on port patency and TIVAP-related venous thromboembolism(VTE). \nMethods: Demographics, cancer types, metastases, vascular access sites, chemotherapy drugs, TIVAP patency and TIVAP related complications were evaluated in 297 patients who had TIVAP implanted and 37 patients who underwent removal in our clinic between 2017-2021. \nResults: TIVAP implanted 297 patients were followed-up for a mean 17.7±16.6 months. TIVAPs were removed in 37 patients due to infection 14(4.7%), occlusion 8(2.7%), VTE 9(3%), malposition 1(0.3%), and treatment completion 10(3.3%). TIVAPs of 270(90.9%) patients were found to be usable for an average of 18.5±17.1 months. Complications of VTE, occlusion, infection and malposition developed in a total of 71(23.9%) patients. In the comparison of develepment of these complications according to the presence of metastasis in patients, it was found to be that they were significantly higher in metastatic patients(47-27.9% / 24-18.6% p","PeriodicalId":212263,"journal":{"name":"Karya Journal of Health Science","volume":"55 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Karya Journal of Health Science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52831/kjhs.1272466","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: Totally implantable venous access port(TIVAP) is of great importance as a vascular access route in the treatment of cancer patients. In this study, we researched the effects of cancer types, metastases, chemotherapeutic drugs, and intervention sites on port patency and TIVAP-related venous thromboembolism(VTE).
Methods: Demographics, cancer types, metastases, vascular access sites, chemotherapy drugs, TIVAP patency and TIVAP related complications were evaluated in 297 patients who had TIVAP implanted and 37 patients who underwent removal in our clinic between 2017-2021.
Results: TIVAP implanted 297 patients were followed-up for a mean 17.7±16.6 months. TIVAPs were removed in 37 patients due to infection 14(4.7%), occlusion 8(2.7%), VTE 9(3%), malposition 1(0.3%), and treatment completion 10(3.3%). TIVAPs of 270(90.9%) patients were found to be usable for an average of 18.5±17.1 months. Complications of VTE, occlusion, infection and malposition developed in a total of 71(23.9%) patients. In the comparison of develepment of these complications according to the presence of metastasis in patients, it was found to be that they were significantly higher in metastatic patients(47-27.9% / 24-18.6% p
目的:全植入式静脉通路(TIVAP)作为一种血管通路在肿瘤患者的治疗中具有重要意义。在这项研究中,我们研究了癌症类型、转移、化疗药物和干预部位对肺动脉通畅和tivap相关静脉血栓栓塞(VTE)的影响。方法:对2017-2021年我院297例植入TIVAP患者和37例切除TIVAP患者的人口统计学、肿瘤类型、转移、血管通路部位、化疗药物、TIVAP通畅度和TIVAP相关并发症进行评估。结果:随访297例患者,平均17.7±16.6个月。37例患者因感染14例(4.7%)、闭塞8例(2.7%)、静脉血栓栓塞9例(3%)、位置错位1例(0.3%)和治疗完成10例(3.3%)而摘除了TIVAPs。270例(90.9%)患者的TIVAPs平均可用时间为18.5±17.1个月。71例(23.9%)患者出现静脉血栓栓塞、闭塞、感染和体位错位等并发症。根据患者是否存在转移比较这些并发症的发生情况,发现转移患者的并发症发生率明显高于转移患者(47-27.9% / 24-18.6% p